102 Alternatively, several groups are advocating with the incorporation of novel markers, such as a elaborate karyotype55 or epigenetic subsets, 27,28 into clinical follow. These novel prognostic and/or predictive designs will have to be validated in cohorts of clients addressed with targeted agents.It is crucial to consider the movement cytometry